Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment.
about
Syndecan-4 Is an Independent Predictor of All-Cause as Well as Cardiovascular Mortality in Hemodialysis PatientsThe role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro-Fibrotic Signaling.Prognostic Significance of Left Ventricular Mass Index and Renal Function Decline Rate in Chronic Kidney Disease G3 and G4.Novel Faces of Fibroblast Growth Factor 23 (FGF23): Iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury.Cigarette smoking causes epigenetic changes associated with cardiorenal fibrosis.Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease - Demystifying controversies.Volume Balance and Intradialytic Ultrafiltration Rate in the Hemodialysis Patient.The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study.Reproducibility and Reliability Of QTc and QTcd Measurements and Their Relationships with Left Ventricular Hypertrophy in Hemodialysis Patients.Early development of podocyte injury independently of hyperglycemia and elevations in arterial pressure in nondiabetic obese Dahl SS leptin receptor mutant rats.Systolic blood pressure values might further risk-stratify the adverse outcomes of LVH in older patients with chronic kidney disease.Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD) - A systematic review and meta-analysis.Premature Coronary Artery Disease and Early Stage Chronic Kidney Disease.[Current insights into anemia in old age : Summary of the symposium "Anemia in old age" on the occasion of the annual congress of the German Society for Geriatrics (DGG) 2016 in Stuttgart].Factors associated with residual urine volume preservation in patients undergoing hemodialysis for end-stage kidney disease in Kinshasa.Mechanical dyssynchrony and diastolic dysfunction are common in LVH: a pilot correlation study using Doppler echocardiography and CZT gated-SPECT MPI.Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH.sST2 as a New Biomarker of Chronic Kidney Disease-Induced Cardiac Remodeling: Impact on Risk PredictionUltrasonic image analysis of longitudinal strain in uremic patients with preserved left ventricular ejection fraction
P2860
Q28554399-48E17B3C-F89E-4FB1-8E77-2A0A4BA6C13FQ36963471-4B0890E4-9B51-4407-81E2-7A764370F900Q37434735-F2B6B5E4-608A-4377-9305-8135D0BB7AC8Q37640240-93CDBD48-0E81-4F10-A123-CFC4902C6542Q39003429-08D79255-A4E6-464C-B46C-40071025E998Q39241512-11EB763D-3C97-47BB-992A-7643F757A29CQ39397039-6CA21D1D-30BC-40D1-9262-0A0124932432Q40084836-C8430D7E-8A7C-4FDB-A12A-E3E076DE6D07Q40200123-BF9139D9-619D-42F6-9A30-803C09985934Q41626887-984044C8-468B-4553-8890-4AE21886C416Q41630778-BB276F7F-ADA7-4774-A32F-919E7733EE99Q42003531-021541FD-82C8-4188-9544-85BD3D94F67BQ47107653-6ED1486B-3038-4F21-870F-55E0881BB9F9Q50099911-F8AE943C-D1AF-490C-A89A-A49C9848D782Q51338559-D5652CCB-3E07-48F2-BE5D-439FC3836407Q52648401-E7742940-425F-4B1C-8BC0-943228F2CE7CQ52665749-1A426496-8250-4E62-A970-E07ED2583E65Q52720297-CDFE8B2D-6791-4E09-B33B-254EB91F1C36Q58580704-AE45F7A5-4861-4DA1-940F-DFDCC2FE2BB5Q58736358-AF421D8B-86E8-45CF-8941-D6F18623EACF
P2860
Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Left Ventricular Hypertrophy i ...... m Pathophysiology to Treatment
@nl
Left Ventricular Hypertrophy i ...... Pathophysiology to Treatment.
@ast
Left Ventricular Hypertrophy i ...... Pathophysiology to Treatment.
@en
type
label
Left Ventricular Hypertrophy i ...... m Pathophysiology to Treatment
@nl
Left Ventricular Hypertrophy i ...... Pathophysiology to Treatment.
@ast
Left Ventricular Hypertrophy i ...... Pathophysiology to Treatment.
@en
prefLabel
Left Ventricular Hypertrophy i ...... m Pathophysiology to Treatment
@nl
Left Ventricular Hypertrophy i ...... Pathophysiology to Treatment.
@ast
Left Ventricular Hypertrophy i ...... Pathophysiology to Treatment.
@en
P2093
P2860
P3181
P356
P1433
P1476
Left Ventricular Hypertrophy i ...... Pathophysiology to Treatment.
@en
P2093
Alberto Santoboni
Antonio Gorini
Domenico Russo
Luca Di Lullo
P2860
P304
P3181
P356
10.1159/000435838
P407
P577
2015-07-15T00:00:00Z